Abstract
A high-throughput screening campaign using a commercial compound library (ChemBridge DiverSET) revealed diverse chemotypes as inhibitors of the human dCTP pyrophosphatase 1 (dCTPase). Triazole, triazolopyrimidine, triazinoindole, quinoline hydrazone and arylpiperazine hits were clustered, confirmed by IC50 determinations, and their preliminary structure-activity-relationships (SAR) and ligand efficiency scores are discussed in this letter.
Copyright © 2017. Published by Elsevier Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Heterocyclic Compounds / chemical synthesis
-
Heterocyclic Compounds / chemistry
-
Heterocyclic Compounds / pharmacology*
-
Humans
-
Hydrazones / chemical synthesis
-
Hydrazones / chemistry
-
Hydrazones / pharmacology
-
Indoles / chemical synthesis
-
Indoles / chemistry
-
Indoles / pharmacology
-
Molecular Structure
-
Piperazines / chemical synthesis
-
Piperazines / chemistry
-
Piperazines / pharmacology
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology
-
Pyrophosphatases / antagonists & inhibitors*
-
Pyrophosphatases / metabolism
-
Quinolines / chemical synthesis
-
Quinolines / chemistry
-
Quinolines / pharmacology
-
Structure-Activity Relationship
-
Triazoles / chemical synthesis
-
Triazoles / chemistry
-
Triazoles / pharmacology
Substances
-
Enzyme Inhibitors
-
Heterocyclic Compounds
-
Hydrazones
-
Indoles
-
Piperazines
-
Pyrimidines
-
Quinolines
-
Triazoles
-
Pyrophosphatases
-
dCTP pyrophosphatase